Seeking Blockbuster, Genzyme Binds Polymer Developer GelTex
Three years ago, Genzyme and GelTex teamed up to commercialize Renagel, the only calcium-free phosphate binding agent used to treat dialysis patients. Now, informed with clinical data showing that calcium plays a role in cardiovascular disease among dialysis patients, the companies have agreed upon a billion-dollar merger. If Renagel's new-found blockbuster expectations are met, the deal will give Genzyme the big-market drug it needs to propel earnings growth.
You may also be interested in...
Big Pharma in-licensing has been kind to anti-infectives start-ups Cubist and Versicor, giving them near-term products and significant valuations. Now Althexis, hoping to capitalize on similar opportunities, is merging with Microcide. The deal is a way of jumpstarting the still nascent Althexis and re-starting Microcide, re-setting its valuation and development clock. With Microcide's cephalosporin, technology-based Althexis would get the product focus it lacked. And the deal comes with $60mm in new money from investors who've bought CEO Mark Skaletsky's vision and want him to repeat his success at GelTex.
The Independent Beauty Association’s Akemi Ooka, head of global supply chain resources, and new board chair Elizabeth Corrigan sat down with HBW Insight to discuss ongoing supply chain challenges, how the trade association’s members are adapting, and prospects for relief ahead.
International Flavors & Fragrances looks for CEO to replace Andreas Fibig; Ultrahuman Healthcare appoints private equity expert as business chief; prebiotics developer Clasado taps nutritional scientist; Abbott kicks off nutritional partnership with Real Madrid; and CRN adjusts membership fees.